drugset / Trial / NCT04677712
Effects of Mitigation Treatments on Bruising of CCH-aaes Treatment of Buttock Cellulite
Phase 4
Completed
48 enrolled
Endo USA Inc., a Keenova Therapeutics Company
Biesman, Brian, M.D. · collabDeNova Research · collabInvestigate MD, LLC · collabLaser & Skin Surgery Medical Group, Inc. · collabMathew Avram, MD · collabPlastic Surgical Associates of Fort Collins, P.C. · collabThe Wall Center for Plastic Surgery · collabUniversity of California, San Diego · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
This study will investigate treatments that may mitigate bruising after QWO™ (Collagenase clostridium histolyticum \[CCH\]-aaes) treatment of cellulite in the buttocks.
Timeline
- Start
- 2020-12-28
- Primary completion
- 2021-06-26
- Completion
- 2021-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | INhance | Unknown | — | Topical |
| Comparator | OcuMend | Unknown | — | — |
| Comparator | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | — | Subcutaneous |